Glenmark Pharmaceuticals Quarterly Results for Trading Insights
GLENMARK • Latest quarterly financial performance to support trade journaling in Tickjournal
Latest Quarter Net Profit
₹610 Cr
QSept 2025
Glenmark Pharmaceuticals Quarterly Results Key Highlights
- Revenue of ₹6,204 Cr in Sept 2025 (+92.0% vs Mar 2025, +80.3% vs Sept 2024)
- Net Profit of ₹610 Cr in Sept 2025 (+15150.0% vs Mar 2025, +71.8% vs Sept 2024)
- EBITDA of ₹1,132 Cr in Sept 2025 (+590.2% vs Mar 2025)
- Operating Margin of 16.0% in Sept 2025 (+11.0pp vs Mar 2025)
- Earnings Per Share of ₹21.63 in Sept 2025 (+13418.8% vs Mar 2025)
Glenmark Pharmaceuticals Quarterly Results Analysis
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,204 | 3,232 | 3,086 | 3,440 | 3,814 | 92.0% | 80.3% |
| Net Profit (₹ Cr) | 610 | 4 | 47 | 355 | -1,214 | - | - |
| EBITDA (₹ Cr) | 1,132 | 164 | 79 | 608 | 808 | - | - |
| EPS (₹) | 21.63 | 0.16 | 1.66 | 12.55 | -43.17 | - | - |
| Operating Margin (%) | 16.0% | 5.0% | 2.0% | 17.0% | 0.0% | - | - |
Glenmark Pharmaceuticals Share Price Trend Around Quarterly Results
Visualize Glenmark Pharmaceuticals's 1-year price movement across quarterly results — ideal for logging trades in Glenmark Pharmaceuticals share price
chart using Tickjournal. All values in ₹.
Related Pages for Glenmark Pharmaceuticals
Additional stock information and data for GLENMARK
Revenue Trend (₹ Cr)
Sept 2024
3,440
Jun 2025
3,086
Mar 2025
3,232
Sept 2025
6,204
Net Profit Trend (₹ Cr)
Sept 2024
355
Jun 2025
47
Mar 2025
4
Sept 2025
610
Operating Margin Trend (%)
Sept 2024
17.0%
Jun 2025
2.0%
Mar 2025
5.0%
Sept 2025
16.0%
Sector Competitors - Quarterly Performance Comparison
Comparing Glenmark Pharmaceuticals quarterly results with other companies in Healthcare sector
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹422,330.94 Cr | 1782.6 | 14,875 | 3,125 | +10.8% | - | 21.0% | 137.1 |
|
Divis Laboratories
Sept 2025 |
₹176,337.50 Cr | 6642.5 | 2,860 | 689 | +7.1% | - | 24.1% | 255.8 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹136,522.12 Cr | 4092.2 | 3,219 | 591 | +11.3% | - | 18.4% | 233.3 |
|
Cipla
Sept 2025 |
₹121,238.47 Cr | 1467.9 | 7,716 | 1,353 | +12.0% | - | 17.5% | 87.7 |
|
Dr Reddys Laborator…
Sept 2025 |
₹104,829.57 Cr | 1242.8 | 9,135 | 1,337 | +1.1% | - | 14.6% | 76.8 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores